Quince Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Dirk Thye

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	41.3%
CEO tenure	2yrs
CEO ownership	1.6%
Management average tenure	2yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Feb 09

Cortexyme: A Fresh Perspective In Alzheimer's

Jan 12

Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?

Dec 18

CEO Compensation Analysis

How has Dirk Thye's remuneration changed compared to Quince Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$550k	-US$31m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$5m	US$317k	-US$52m

Compensation vs Market: Dirk's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD674.46K).

Compensation vs Earnings: Dirk's compensation has been consistent with company performance over the past year.

CEO

Dirk Thye (53 yo)

2yrs

Tenure

US$1,330,500

Compensation

Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dirk Thye	CEO, Chief Medical Officer & Director	2yrs	US$1.33m	1.6% $ 684.9k
Charles Ryan	President	less than a year	US$1.11m	0.17% $ 73.6k
Brendan Hannah	Chief Business Officer	1.2yrs	US$847.50k	0.47% $ 200.2k
Guenter Janhofer	Chief Scientific Officer	less than a year	no data	0.035% $ 14.9k
Stacy Roughan	Vice President of Corporate Communications & Investor Relations	3.3yrs	no data	no data
Mary Sillivos	Vice President of Human Resources	4.3yrs	no data	no data
Stewart Low	Head of Discovery	2yrs	no data	no data

2.0yrs

Average Tenure

53yo

Average Age

Experienced Management: QNCX's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dirk Thye	CEO, Chief Medical Officer & Director	2yrs	US$1.33m	1.6% $ 684.9k
Una Ryan	Lead Independent Director	5.3yrs	US$98.56k	0.0066% $ 2.9k
Ilan Zipkin	Member of Scientific Advisory Board	no data	US$44.84k	no data
Jeffrey Cummings	Member of Clinical Advisory Board	4.9yrs	no data	no data
Martin Farlow	Member of Clinical Advisory Board	no data	no data	no data
David Lamond	Independent Chairman of the board	8.4yrs	US$106.06k	10.14% $ 4.4m
Christopher Senner	Independent Director	5.2yrs	US$87.56k	0% $ 0
Margaret McLoughlin	Independent Director	8.4yrs	US$82.06k	0.019% $ 7.9k
Mark Brody	Member of Clinical Advisory Board	no data	no data	no data
David Munoz	Member of Clinical Advisory Board	no data	no data	no data
Mark Ryder	Member of Clinical Advisory Board	no data	no data	no data
Mauro Magnani	Chairman of Scientific Advisory Board	less than a year	no data	no data

5.2yrs

Average Tenure

57.5yo

Average Age

Experienced Board: QNCX's board of directors are considered experienced (5.2 years average tenure).

Quince Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Recent updates

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29

Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index

Independent Director Kevin Young has left the company

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Cortexyme EPS beats by $0.02

We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Price target decreased to US$66.63

Independent Director recently bought US$1.7m worth of stock

Independent Director recently bought US$1.8m worth of stock

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Cortexyme Announces Partnership with Parkinson Study Group